Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study
Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study
复制标题
DOI：
10.1111/liv.12588
复制
发表时间：
2015-01-01
影响因子：
6.7
通讯作者：
Shulman, Nancy S.
中科院分区：
文献类型：
--
作者：
Gane, Edward J.;Pockros, Paul J.;Shulman, Nancy S.
背景与目的：即使加入直接作用的抗病毒药物，以聚乙二醇干扰素为基础的丙型肝炎病毒（HCV）感染治疗的安全性和耐受性仍不理想。本研究评估了mericitabine联合利托那韦增强的danoprevir的疗效、安全性和耐受性在未经治疗的HCV基因型（G）1感染患者中，使用达诺普韦/r利巴韦林长达24周。（100 mg/100 mg）加利巴韦林（1000/1200 mg/天; A组）或安慰剂（B组）治疗12或24周。HCV RNA患者
Background & AimsSafety and tolerability of peginterferon-based hepatitis C virus (HCV) infection therapy remains suboptimal, even when direct-acting antiviral agents are added. This study assessed the efficacy, safety and tolerability of mericitabine combined with ritonavir-boosted danoprevir (danoprevir/r)ribavirin for up to 24weeks in treatment-naive HCV genotype (G)1 infected patients.MethodsPatients received twice daily mericitabine (1000mg) and danoprevir/r (100mg/100mg) plus either ribavirin (1000/1200mg/day; Arm A) or placebo (Arm B) for 12 or 24weeks. Patients with HCV RNA